IPO Postponement Aims to Avoid Summer Market Turbulence
Germany-based medtech company Brainlab has decided to put its highly anticipated initial public offering (IPO) on hold, rescheduling its debut on the Frankfurt Stock Exchange to early 2025. The decision comes as market volatility and seasonal trading lulls prompt companies to seek more favorable conditions.
Originally Planned for Summer Launch
- Brainlab had announced its intention to go public in late June 2025, targeting a price range of €80 to €100 per share.
- The IPO was set to place Brainlab among a record-setting year for medtech IPOs, with the sector poised to surpass totals from the past two years combined[3].
- The new timeline moves Brainlab’s IPO from the traditional summer window—often characterized by diminished investor activity—to the start of 2025, aiming for a stronger and more stable market environment.
Growth Ambitions Remain Unchanged
Despite the delay, Brainlab’s ambitious growth targets remain in place:
- The company aims for a 10–13% compound annual revenue growth rate and an EBITDA margin in the mid-20s.
- Expansion plans span new clinical areas such as orthopedics, sports medicine, and cardiovascular interventions[1].
- Proceeds from the offering are expected to fund growth initiatives, particularly expanding into new clinical markets and strengthening sales and research teams.
IPO Structure and Market Impact
- The offering structure includes both primary shares (2.0 million) to fund the business and secondary shares (up to 3.2 million) from private equity and management-linked entities.
- Total potential proceeds could reach up to €520 million, supporting expansion and R&D investments[1].
- After the IPO, a projected 26.6% free float is set to ensure sufficient liquidity for active trading.
Strategic Moves: Snke Spin-off
In parallel with its IPO plans, Brainlab recently announced the spin-off of its group Snke, which will now focus independently on integrating medical research, education, and treatment through advanced IT infrastructure for hospitals[2]. This move allows Brainlab to sharpen its focus on profitable growth while Snke scales up technology leadership in the healthtech domain.
Medtech IPO Momentum Unabated
Brainlab’s offering is part of a broader surge in [medtech IPOs](https://www.bioworld.com/articles/721142-med-tech-ipos-gain-steam-going-into-q3) as the industry continues to witness record-breaking public market activity in 2025[3]. The company’s re-timing reflects broader market strategies to maximize investor interest and ensure successful listings.
